Caris Life Sciences, Inc. $CAI Shares Purchased by Perceptive Advisors LLC

Perceptive Advisors LLC increased its holdings in shares of Caris Life Sciences, Inc. (NASDAQ:CAI) by 3.5% during the 4th quarter, Holdings Channel.com reports. The fund owned 1,136,206 shares of the company’s stock after buying an additional 38,043 shares during the period. Perceptive Advisors LLC’s holdings in Caris Life Sciences were worth $30,655,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also recently bought and sold shares of CAI. Global Retirement Partners LLC raised its stake in Caris Life Sciences by 99,900.0% during the fourth quarter. Global Retirement Partners LLC now owns 1,000 shares of the company’s stock worth $27,000 after acquiring an additional 999 shares during the period. Olistico Wealth LLC acquired a new stake in Caris Life Sciences during the fourth quarter worth about $31,000. MetLife Investment Management LLC raised its stake in Caris Life Sciences by 84.0% during the fourth quarter. MetLife Investment Management LLC now owns 1,654 shares of the company’s stock worth $45,000 after acquiring an additional 755 shares during the period. Aster Capital Management DIFC Ltd acquired a new stake in shares of Caris Life Sciences in the fourth quarter valued at approximately $67,000. Finally, Federated Hermes Inc. acquired a new stake in shares of Caris Life Sciences in the fourth quarter valued at approximately $81,000.

Caris Life Sciences Trading Down 0.7%

Shares of NASDAQ:CAI opened at $17.86 on Thursday. The company has a 50 day moving average price of $17.72. Caris Life Sciences, Inc. has a 52 week low of $14.19 and a 52 week high of $42.50. The firm has a market capitalization of $5.05 billion and a price-to-earnings ratio of -2.35. The company has a quick ratio of 6.52, a current ratio of 7.05 and a debt-to-equity ratio of 0.64.

Caris Life Sciences declared that its board has initiated a stock repurchase plan on Monday, June 8th that authorizes the company to repurchase $100.00 million in shares. This repurchase authorization authorizes the company to repurchase up to 2.2% of its stock through open market purchases. Stock repurchase plans are usually a sign that the company’s board of directors believes its stock is undervalued.

Analyst Ratings Changes

Several brokerages have commented on CAI. BTIG Research dropped their price target on shares of Caris Life Sciences from $38.00 to $32.00 and set a “buy” rating on the stock in a research note on Friday, May 8th. Citigroup dropped their price target on shares of Caris Life Sciences from $35.00 to $28.00 and set a “buy” rating on the stock in a research note on Friday, May 8th. The Goldman Sachs Group began coverage on shares of Caris Life Sciences in a research note on Wednesday, April 1st. They issued a “buy” rating and a $27.00 price target on the stock. Wolfe Research lowered shares of Caris Life Sciences from an “outperform” rating to a “peer perform” rating in a research note on Monday, June 1st. Finally, Jefferies Financial Group began coverage on shares of Caris Life Sciences in a research note on Monday, April 13th. They issued a “buy” rating and a $28.00 price target on the stock. Six research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $27.56.

Insider Activity

In related news, Director Jeff L. Vacirca acquired 31,050 shares of the firm’s stock in a transaction dated Monday, May 11th. The stock was acquired at an average cost of $16.15 per share, for a total transaction of $501,457.50. Following the completion of the acquisition, the director directly owned 49,671 shares of the company’s stock, valued at approximately $802,186.65. The trade was a 166.75% increase in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. 50.00% of the stock is owned by company insiders.

Caris Life Sciences Profile

Caris Life Sciences (NASDAQ: CAI) is a molecular science company focused on advancing precision medicine in oncology. The company develops and delivers comprehensive molecular profiling services designed to identify actionable biomarkers across DNA, RNA and protein modalities. Its clinical services are intended to support oncologists in treatment decision-making by matching patients to targeted therapies, immunotherapies and relevant clinical trials based on tumor biology.

Caris provides laboratory-based diagnostic testing and related interpretive reports, combining high-throughput sequencing and other molecular technologies with bioinformatic analysis.